The non-antibiotic properties of tetracyclines: Clinical potential in ophthalmic disease

Pharmacological Research

Volumn 64, Issue 6, 2011, Pages 614-623

  Federici, Thomas J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Chemically modified non antibacterial tetracyclines; Choroidal neovascularization; Corneal neovascularization; Retinal neovascularization; Tetracycline

Indexed keywords

ACETYLSALICYLIC ACID; CASPASE; DEXAMETHASONE; DOXYCYCLINE; FAS LIGAND; FLURBIPROFEN; GELATINASE A; GELATINASE B; LOW MOLECULAR WEIGHT HEPARIN; MINOCYCLINE; OMEGA 3 FATTY ACID; OXYTETRACYCLINE; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; RANIBIZUMAB; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; APOPTOSIS; ARTICLE; BLEPHARITIS; CATARACT; CATARACTOGENESIS; CORNEA NEOVASCULARIZATION; CORNEA PERMEABILITY; CORNEA ULCER; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRY EYE; ENZYME INHIBITION; EYE DISEASE; HUMAN; LOW DRUG DOSE; MEIBOMIAN GLAND DYSFUNCTION; MICROGLIA; NONHUMAN; OCULAR ROSACEA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA CELL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; TEAR FILM;

ANIMALS; CASPASE 1; CYTOKINES; ENZYME INHIBITORS; EYE DISEASES; EYE PROTEINS; HUMANS; MATRIX METALLOPROTEINASES; NERVE GROWTH FACTORS; NITRIC OXIDE; SERPINS; TETRACYCLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054123641     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.06.013     Document Type: Article

References (118)

1. C.R. Stephens, L.H. Conover, R. Pasternak, F.A. Hochstein, W.T. Moreland, and P.P. Regna The structure of aureomycin J Am Chem Soc 76 1954 3568 3575
2. M.L. Nelson Chemical and biological dynamics of tetracyclines Adv Dent Res 12 1998 5 11
3. L.M. Golub, K. Soummalainen, and T. Sorsa Host modulation with tetracyclines and their chemically modified analogues Curr Opin Dent 2 1992 80 90
4. A.N. Sapadin, and R. Fleischmajer Tetracylines: nonantibiotic properties and their clinical implications J Am Acad Dermatol 54 2006 258 265 (Pubitemid 43144395)
5. H.D. Perry, and L.M. Golub Systemic tetracyclines in the treatment of noninfected corneal ulcers: a case report and proposed new mechanism of action Ann Ophthalmol 17 1985 742 744 (Pubitemid 16178500)
6. J.P. Gilbard, R.L. Farris, and J. Santamaria II Osmolarity of tear microvolumes in keratoconjunctivitis sicca Arch Ophthalmol 96 1978 677 681 (Pubitemid 8301697)
7. J.P. Gilbard The scientific context and basis of the pharmacologic management of dry eyes Ophthalmol Clin N Am 18 2005 475 484 (Pubitemid 41728017)
8. 2-terminal kinase pathway Invest Ophthalmol Vis Sci 43 1981 [E-abstract]
9. L. Luo, D.Q. Li, A. Doshi, W.J. Farley, R.M. Corrales, and S.C. Pflugfelder Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 activates MAPK signaling pathways on the ocular surface Invest Ophthalmol Vis Sci 45 2004 4293 4301 (Pubitemid 39564653)
10. L. Luo, D.Q. Li, R.M. Corrales, and S.C. Pflugfelder Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface Eye Contact Lens 31 2005 186 193 (Pubitemid 43197004)
11. C.S. De Paiva, R.M. Corrales, A.L. Villarreal, W.J. Farley, D.Q. Li, and M.E. Stern Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye Exp Eye Res 83 2006 526 535 (Pubitemid 43902774)
12. C.S. De Paiva, R.M. Corrales, A.L. Villarreal, W.J. Farley, D.Q. Li, and M.E. Stern Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline Invest Ophthalmol Vis Sci 47 2006 2847 2856 (Pubitemid 351639757)
13. R.M. Beardsley, C.S. De Paiva, D.F. Power, and S.C. Pflugfelder Desiccation stress decreases apical corneal epithelial cell size - modulation by the metalloproteinase inhibitor doxcycline Cornea 27 2008 935 940
14. H.S. Kim, L. Luo, C. Pflugfelder, and D.Q. Li Doxycycline inhibits TGF-β1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells Invest Ophthalmol Vis Sci 46 2005 840 848 (Pubitemid 41321019)
15. V.A. Smith, and S.D. Cook Doxycycline - a role in ocular surface repair Br J Ophthalmol 88 2004 619 625 (Pubitemid 38526642)
16. H. Seitsalo, R.K. Niemela, M. Marinescu-Gava, T. Vuotila, L. Tjaderhane, and T. Salo Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjogren's Syndrome: a randomized, double-blind, placebo controlled cross-over study J Negat Results Biomed 6 2007 11
17. A.J Bron, J.M. Tiffany, S.M. Gouveia, N. Yokoi, and L.W. Von Functional aspects of the tear film lipid layer Exp Eye Res 78 2004 347 360 (Pubitemid 38183311)
18. J.P. McCulley, J.M. Dougherty, and D.G. Deneau Classification of chronic blepharitis Ophthalmology 89 1982 1173 1180 (Pubitemid 12003236)
19. W.D. Mathers, J.A. Lane, J.E. Sutphin, and M.B. Zimmerman Model for ocular tear film function Cornea 15 1996 110 119 (Pubitemid 26061307)
20. W.E. Shine, and J.P. McCulley Meibomian gland triglyceride fatty acid differences in chronic blepharitis patients Cornea 15 1996 340 346 (Pubitemid 26189972)
21. M. Souchier, C. Joffre, S. Gregoire, L. Bretillon, A. Muselier, and N. Acar Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment Br J Ophthalmol 92 2008 819 822 (Pubitemid 351839576)
22. S.E. Yoo, D.C. Lee, and M.H. Chang The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction Korean J Ophthalmol 19 2005 258 263
23. M.S. Macsai The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis) Trans Am Ophthalmol Soc 106 2008 336 356
24. J.M. Dougherty, J.P. McCulley, R.E. Silvany, and D.R. Meyer The role of tetracycline in chronic blepharitis: inhibition of lipase production in Staphylococci Invest Ophthalmol Vis Sci 32 1991 2970 2975
25. J.D. Aronowicz, W.E. Shine, D. Oral, J.M. Vargas, and J.P. McCulley Short term oral minocycline treatment of meibomianitis Br J Ophthalmol 90 2006 856 860 (Pubitemid 43973996)
26. El. Tolman Acne and acneiform dermatoses S.L. Moschella, J.F. Hurley, Dermatology vol. 2 1992 WB Saunders Philadelphia 1477 1492
27. D. Browning, and A. Proia Ocular rosacea Surv Ophthalmol 31 1986 145 158 (Pubitemid 17222026)
28. E. Tanzi, and J. Weinberg The ocular manifestations of rosacea Cutis 68 2001 112 114 (Pubitemid 33757342)
29. E.K. Akpek, A. Merchant, V. Piinar, and C.S. Foster Ocular rosacea: patient characteristics and follow-up Ophthalmology 104 1997 1863 1867 (Pubitemid 28100343)
30. R.S. Bartholomew, B.J. Reid, M.J. Cheesbroug, M. Macdonald, and N.R. Galloway Oxytetracycline in the treatment of ocular rosacea: a double-blind trial Br J Ophthalmol 66 1982 386 388 (Pubitemid 12081691)
31. M.J. Quarterman, D.W. Johnson, D.C. Abele, J.L. Lesher, D.S. Hull, and L.S. Davis Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline Arch Dermatol 133 1997 49 54 (Pubitemid 27044305)
32. A. Cetinkaya, and Y.A. Akova Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics Am J Ophthalmol 142 2006 816 821
33. D.U. Stone, and J. Chodosh Oral tetracyclines for ocular rosacea: an evidence-based review of the literature Cornea 23 2004 106 109 (Pubitemid 38031886)
34. R.A. Ralph Tetracyclines and the treatment of corneal stromal ulceration: a review Cornea 19 2000 274 277 (Pubitemid 30322447)
35. J.A. Seedor, H.D. Perry, T.F. McNamara, L.M. Golub, D.F. Buxton, and D.S. Guthrie Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits Arch Ophthalmol 105 1987 268 271 (Pubitemid 17013713)
36. L. Szmyd Jr., S.M. Spector, H.D. Perry, J.A. Seedor, T.F. McNamara, and L.M. Golub Topical tetracycline in the treatment of alkali-induced corneal ulceration in the rabbit Invest Ophthalmol Vis Sci 27 Suppl. 1986 208
37. F.R. Burns, M.S. Stack, R.D. Gray, and C.A. Paterson Inhibition of purified collagenase from alkali-burned rabbit corneas Invest Ophthalmol Vis Sci 30 1989 1569 1575 (Pubitemid 19185960)
38. H.D. Perry, K.R. Kenyon, D.W. Lamberts, G.N. Foulks, J.A. Seedor, and L.M. Golub Systemic tetracycline hydrochloride as adjunctive therapy in the treatment of persistent epithelial defects Ophthalmology 93 1986 1320 1322 (Pubitemid 16008997)
39. G.A. Peyman, A.A. Kazi, M. Riazi-Esfahani, E. Aydin, M. Kivilcim, and D.R. Sanders The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization Cornea 25 2006 582 585 (Pubitemid 44620104)
40. M. Riazi-Esfahani, G.A. Peyman, E. Aydin, A.A. Kazi, M. Kivilcim, and D.R. Sanders Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model Cornea 25 2006 801 805 (Pubitemid 44657255)
41. E. Aydin, M. Kivilcim, G.A. Peyman, M.R. Esfahani, A.A. Kazi, and D.R. Sanders Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline Cornea 27 2008 446 453 (Pubitemid 351591483)
42. L. Dan, Y. Shi-long, L. Miao-li, L. Yong-ping, M. Hong-jie, and Z. Ying Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis Curr Eye Res 33 2008 653 660
43. F.J. Deschamps, E. Martens, P. Proost, S. Starckx, P.E. Van den Steen, and J. Van Damme Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens βB1 crystallin FASEB J 19 2005 29 35 (Pubitemid 40069917)
44. N.H. Sachdev, N. Di Girolamo, T.M. Nolan, P.J. McClucskey, D. Wakefield, and M.T. Coroneo Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the human lens: implications for cortical cataract formation Invest Ophthalmol Vis Sci 45 2004 4075 4082 (Pubitemid 39411163)
45. D.J. Dwivedi, G. Pino, A. Ban, Z. Nathu, D. Howchin, and P. Margetts Matrix metalloproteinase inhibitors suppress transforming growth factor-β-induced subcapsular cataract formation Am J Pathol 168 2006 69 79 (Pubitemid 43062560)
46. D.M. Richiert, and M.E. Ireland Matrix metalloproteinase secretion is stimulated by TFG-β in cultured lens epithelial cells Curr Eye Res 19 1999 269 275 (Pubitemid 29500277)
47. J.A. West-Mays Matrix metalloproteinases as mediators of primary and secondary cataracts Expert Rev Ophthalmol 2 2007 931 938
48. M.E. Ryan, N.S. Ramamaurthy, T. Sorsa, and L.M. Golub MMP-mediated events in diabetes Ann NY Acad Sci 878 1999 311 334 (Pubitemid 29353578)
49. B.E. Klein, R. Klein, and K.E. Lee Diabetes, cardiovascular disease, selected cardiovascular risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study Am J Ophthalmol 126 1998 782 790 (Pubitemid 29001627)
50. A. Hennis, S. Wu, B. Nemesure, and C. Leske Risk factors for the incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies Arch Ophthalmol 122 2004 525 530 (Pubitemid 38456288)
51. H.D. Schubert Retinal and choroidal circulation M. Yanoff, J.S. Duker, Ophthalmology 2004 Mosby China 511 514
52. S.X. Zhang, and J. Ma Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy Prog Retin Eye Res 26 2007 1 37 (Pubitemid 44920203)
53. A. Kvanta Ocular angiogenesis: the role of growth factors Acta Ophthalmol Scand 84 2006 282 288
54. The Diabetic Retinopathy Study Group Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8 Ophthalmology 88 1981 583 600
55. Early Treatment Diabetic Retinopathy Treatment Group Early photocoagulation for diabetic retinopathy. ETDRS report number 9 Ophthalmology 98 1991 766 785
56. A.M. Joussen, T. Murata, A. Tsujikawa, B. Kirchof, S.E. Bursell, and A.P. Adamis Leukocyte-mediated endothelial cell injury and death in the diabetic retina Am J Pathol 158 2001 147 152 (Pubitemid 32096479)
57. H. Funatsu, H. Yamashita, H. Noma, T. Mimra, T. Yamashita, and S. Hori Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema Am J Ophthalmol 133 2002 70 77 (Pubitemid 34076505)
58. D. Giulian, J. Li, S. Bartel, J. Broker, X. Li, and J.B. Kirkpatrick Cell surface morphology identifies microglia as a distinct class of mononuclear phagocyte J Neurosci 15 1995 7712 7726
59. W.J. Streit, M.B. Graeber, and G.W. Kreutzberg Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system J Neuroimmmunol 21 1989 117 123 (Pubitemid 19031379)
60. W.J. Streit, and G.W. Kreutzberg Response of endogenous glial cells to motor neuron degeneration induced by toxic ricin J Comp Neurol 268 1988 248 263
61. J.K. Krady, A. Basu, C.M. Allen, Y. Xu, K.F. LaNoue, and T.W. Gardner Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy Diabetes 54 2005 1559 1565 (Pubitemid 40586690)
62. A.L. Wang, A.C. Yu, L.T. Lau, C. Lee, M. Wu le, and X. Zhu Minocycline inhibits LPS-induced retinal microglia activation Neurochem Int 47 2005 152 158 (Pubitemid 40848704)
63. J.A. Vincent, and S. Mohr Inhibition of caspase-1/interleukin-1β signaling prevents degeneration of retinal capillaries in diabetes and galactosemia Diabetes 56 2007 224 230
64. D.W. Nicholson, and N.A. Thornberry Caspases: killer proteases Trends Biochem Sci 22 1997 299 306 (Pubitemid 27327087)
65. S. Mohr, X. Xi, J. Tang, and T.S. Kern Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients Diabetes 51 2002 2007 2012
66. S. Mohr Potential new strategies to prevent the development of diabetic retinopathy Expert Opin Investig Drugs 13 2004 189 198 (Pubitemid 38351341)
67. F. Hao, and J.D. Yu High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells Acta Pharmacol Sin 24 2003 534 538
68. S. Uemura, H. Matsushita, W. Li, A.J. Glassford, T. Asagami, and K.H. Lee Diabetes mellitus enhances vascular matrix metalloproteinase activity. Role of oxidative stress Circ Res 88 2001 1291 1298 (Pubitemid 32587846)
69. A. Das, P.G. McGuire, C. Eriqat, R.R. Ober, E. DeJuan Jr., and G.A. Williams Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes Invest Ophthalmol Vis Sci 40 1999 809 813 (Pubitemid 29109465)
70. A. Das, A. McLemore, W.S. Song, and P.G. McGuire Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor Arch Ophthalmol 117 1998 498 503
71. K. Noda, S. Ishida, M. Inoue, K. Obata, Y. Oguchi, and Y. Okada Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy Invest Ophthalmol Vis Sci 33 2003 2163 2170 (Pubitemid 36520313)
72. L.K. Bhatt, and V. Addepalli Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats Am J Transl Res 2 2010 181
73. R.B. Nussenblatt, and F. Ferris III Age-related macular degeneration and the immune response: implications for therapy Am J Ophthalmol 144 2007 618 626
74. J. Ambati, B.K. Ambati, S.H. Yoo, S. Ianchulev, and A.P. Adamis Age-related macular degeneration: aetiology, pathogenesis, and therapeutic strategies Surv Ophthalmol 48 2003 257 293 (Pubitemid 36553096)
75. Y. Qazi, S. Maddula, and B.K. Ambati Mediators of ocular angiogenesis J Genet 88 2009 495 515
76. S. Hoffman, S. He, M. Ehren, S.J. Ryan, P. Wiedemann, and S. Tanaka MMp-2 and MMP-9 secretion by rpe is stimulated by angiogenic molecules fond in choroidal neovascular membranes Retina 26 2006 454 461 (Pubitemid 44197638)
77. B. Steen, S. Sejersen, L. Berglin, S. Seregard, and A. Kvanat Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes Invest Ophthalmol Vis Sci 39 1998 2194 2200 (Pubitemid 28455093)
78. A. Kvanta, W.Y. Shen, S. Sarman, S. Seregard, B. Steen, and E. Rakoczy Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization Curr Eye Res 21 2000 684 690 (Pubitemid 32000587)
79. A. Kvanta, S. Sarman, P. Fagerholm, S. Seregard, and B. Steen Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization Exp Eye Res 70 2000 419 428 (Pubitemid 30658885)
80. S. Samtani, J. Amaral, M.M. Campos, Rn. Fariss, and S.P. Becerra Doxycycline-mediated inhibition of choroidal neovascularization Invest Ophthalmol Vis Sci 50 2009 5098 5106
81. T.S. Griffith, T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270 1995 1189 1192
82. H.O. Lee, J.M. Herndon, R. Barreiro, T.S. Griffith, and T.A. Ferguson TRAIL: a mechanism of tumor surveillance in an immune privileged site J Immunol 169 2002 4739 4744 (Pubitemid 35217135)
83. T.A. Feguson, and D.R. Green Fas-ligand and immune privilege: the eyes have it Cell Death Differ 8 2001 771 772 (Pubitemid 32685175)
84. H.J. Kaplan, M.A. Leibole, T. Tezel, and T.A. Feguson Fas ligand (CD95 ligand) controls angiogenesis beneath the retina Nat Med 5 1999 292 297 (Pubitemid 29124364)
85. J. Roychoudhury, J.M. Herndon, J. Yin, R.S. Apte, and T.A. Ferguson Targeting immune privilege to prevent pathogenic neovascularization Invest Ophthalmol Vis Sci 51 2010 3560 3566
86. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983 983 985
87. N. Ferrara, K.A. Houck, L.B. Jakeman, J. Winer, and D.W. Leung The vascular endothelial growth factor family of polypeptides J Cell Biochem 47 1991 211 218
88. W.G. Robers, and G.E. Palade Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor J Cell Sci 108 1995 2369 2379
89. T. Ishibashi, Y. Haata, H. Yoshikawa, K. Nakagawa, K. Sueishi, and H. Inomata Expressioin of vascular endothelial growth factor in experimental choroidal neovascularization Graefes Arch Clin Exp Ophthalmol 235 1997 159 167 (Pubitemid 27129479)
90. X. Yi, N. Ogata, M. Komada, C. Yamamoto, K. Takahashi, and K. Omori Vascular endothelial growth factor expression in choroidal neovascularization in rats Graefes Arch Clin Exp Ophthalmol 235 1997 313 319
91. N. Kwak, N. Okamoto, J.M. Wood, and P.A. Campochiaro VEGF is a mojo stimulator in model of choroidal neovascularization Invest Ophthalmol Vis Sci 41 2000 3158 3164
92. M.G. Krzystolik, M. Afshari, A.P. Adamis, J. Gaudreault, E.S. Gragoudas, and N.A. Michaud Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 2002 338 346 (Pubitemid 34250056)
93. P. Carmeliet, V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, and M. Gertsenstein abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 380 1996 435 439 (Pubitemid 26102719)
94. The Moorfields Macular Study Group Treatment of senile disciform macular degeneration: a single-blind randomized trial by argon laser photocoagulation Br J Ophthalmol 66 1982 745 753
95. Macular Photocoagulation Study Group Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial Arch Ophthalmol 100 1982 912 918
96. Macular Photocoagulation Study Group Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials Arch Ophthalmol 104 1986 694 701
97. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1 Arch Ophthalmol 117 1999 1329 1345
98. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2 Arch Ophthalmol 119 2001 198 207
99. Verteporfin in Photodynamic Therapy Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2 Am J Ophthalmol 131 2001 541 560
100. U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G.O. Naumann Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF) receptor 3, and pigment epithelial derived growth factor Invest Ophthalmol Vis Sci 44 2003 4473 4480 (Pubitemid 37186285)
101. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr., M. Feinsod, D.R. Guyer for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib sodium for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816 (Pubitemid 40051904)
102. L.J. Singerman, H. Masonson, M. Patel, A.P. Adamis, R. Buggage, and E. Cunningham Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial Br J Ophthalmol 92 2008 1606 1611
103. D. Brown, P.K. Kaiser, M. Michels, G. Soubrane, J.S. Heier, and R.Y. Kim Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
104. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, and C.Y. Chung Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
105. N.M. Bressler, T.S. Chang, I.J. Suner, J.T. Fine, C.M. Dolan, and J. Ward Vision-related function after ranibizumab treatment for better- or worse-seeing eye. Clinical trial results from MARINA and ANCHOR Ophthalmology 117 2010 747 756
106. C.Z. Lee, J.S. Yao, Y. Huang, W. Zhai, W. Liu, and B.J. Guglielmo Dose response effects on cerebral matrix metalloproteinases-9 after vascular endothelial growth factor hyperstimulation J Cereb Blood Flow Metab 26 2006 1157 1164 (Pubitemid 44268178)
107. M. Kothari, and S.R. Simon Chemically modified tetracyclines inhibit VEGF secretion by breast cancer cell lines Cytokine 35 2006 115 125 (Pubitemid 44666426)
108. O. Fainaru, I. Adini, O. Benny, L. Bazinet, E. Pravda, and R. D'Amato Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability FASEB J 22 2008 3728 3735
109. C.A. Cox, J. Amaral, R. Salloum, L. Guedez, T.W. Reid, and C. Jaworski Doxycycline's effect on ocular angiogenesis: an in vivo analysis Ophthalmology 117 2010 1782 1791
110. S. Sivaprasad, S. Patra, J. DaCosta, T. Adewoyin, O. Shona, and E. Pearce A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration Ophthalmologica 225 2011 200 206
111. The Eye Diseases Prevalence Group Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 2004 477 485
112. The Eye Diseases Prevalence Group Prevalence of cataract and pseudophakia/aphakia among adults in the United States Arch Ophthalmol 122 2004 487 494
113. The Eye Diseases Prevalence Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
114. X. Zhang, J.B. Saaddine, C.F. Chou, M.F. Cotch, Y.J. Cheng, and L.S. Geiss Prevalence of diabetic retinopathy in the United States, 2005-2008 JAMA 304 2010 649 656
115. J.P. Boyle, T.J. Thompson, E.W. Gregg, L.E. Barker, and D.F. Williamson Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence Popul Health Metr 8 2010 29
116. G.C. Brown Vision and quality-of-life Trans Am Ophthalmol Soc 97 1999 473 511 (Pubitemid 30106064)
117. R.A. Greenwald, S.A. Moak, N.S. Ramamurthy, and L.M. Golub Tetracycline suppresses metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen ameliorates bone damage J Rheumatol 19 1992 927 938
118. H.M. Lee, S.G. Ciancio, G. Tüter, M.E. Ryan, E. Komaroff, and L.M. Golub Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug J Periodontol 75 2004 453 463 (Pubitemid 38461128)